373
Views
39
CrossRef citations to date
0
Altmetric
Original Research

Favipiravir Use in COVID-19: Analysis of Suspected Adverse Drug Events Reported in the WHO Database

ORCID Icon, ORCID Icon, ORCID Icon, ORCID Icon, ORCID Icon, ORCID Icon, ORCID Icon, ORCID Icon, ORCID Icon, ORCID Icon & ORCID Icon show all
Pages 4427-4438 | Published online: 14 Dec 2020

Keep up to date with the latest research on this topic with citation updates for this article.

Read on this site (2)

Musim Alotaibi, Ahmed Ali, Duaa Bakhshwin, Yasser Alatawi, Sultan Alotaibi, Abdullah Alhifany, Badr Alharthi, Nasser Alharthi, Awatef Alyazidi, Yasmeen Alharthi & Aziza Alrafiah. (2021) Effectiveness and Safety of Favipiravir Compared to Hydroxychloroquine for Management of Covid-19: A Retrospective Study. International Journal of General Medicine 14, pages 5597-5606.
Read now
Rimple Jeet Kaur, Siddhartha Dutta, Jaykaran Charan, Pankaj Bhardwaj, Ankita Tandon, Dharamveer Yadav, Salequl Islam & Mainul Haque. (2021) Cardiovascular Adverse Events Reported from COVID-19 Vaccines: A Study Based on WHO Database. International Journal of General Medicine 14, pages 3909-3927.
Read now

Articles from other publishers (37)

Amrita Chatterjee, Rajdeep Saha, Arpita Mishra, Deepak Shilkar, Venkatesan Jayaprakash, Pawan Sharma & Biswatrish Sarkar. (2023) Molecular Determinants, Clinical Manifestations and Effects of Immunization on Cardiovascular Health During COVID-19 Pandemic Era - A Review. Current Problems in Cardiology 48:8, pages 101250.
Crossref
Sarawut Krongsut, Wipasiri Naraphong, Pannaporn Thongsuk & Panupong Tantirat. (2023) COMPARISON OF THE EFFECTIVENESS OF REMDESIVIR VERSUS FAVIPIRAVIR ON CLINICAL IMPROVEMENT AND MORTALITY AMONG PATIENTS WITH COVID-19 PNEUMONIA: A RETROSPECTIVE SINGLE-CENTER STUDY. Journal of Southeast Asian Medical Research 7, pages e0151.
Crossref
Worapong Sungsana, Chotirat Nakaranurack, Benjabhorn Weeraphon, Watsa Charoenwaiyachet, Supparat Chanprasert, Pattama Torvorapanit, Wichai Santimaleeworagun & Opass Putcharoen. (2023) Telepharmacy during home isolation: drug-related problems and pharmaceutical care in COVID-19 patients receiving antiviral therapy in Thailand. Journal of Pharmaceutical Policy and Practice 16:1.
Crossref
Amal Oweid Almutairi, Mahmoud Zaki El-Readi, Mohammad Althubiti, Yosra Zakariyya Alhindi, Nahla Ayoub, Abdullah R. Alzahrani, Saeed S. Al-Ghamdi & Safaa Yehia Eid. (2023) Liver Injury in Favipiravir-Treated COVID-19 Patients: Retrospective Single-Center Cohort Study. Tropical Medicine and Infectious Disease 8:2, pages 129.
Crossref
Surojit Banerjee, Debadri Banerjee, Anupama Singh, Sumit Kumar, Deep Pooja, Veerma Ram, Hitesh Kulhari & Vikas Anand Saharan. (2023) A Clinical Insight on New Discovered Molecules and Repurposed Drugs for the Treatment of COVID-19. Vaccines 11:2, pages 332.
Crossref
Armedy R. Hasugian. 2023. Proceedings of the 1st International Conference for Health Research – BRIN (ICHR 2022). Proceedings of the 1st International Conference for Health Research – BRIN (ICHR 2022) 767 773 .
Vuyolwethu Khwaza, Buhle Buyana, Xhamla Nqoro, Sijongesonke Peter, Zintle Mbese, Zizo Feketshane, Sibusiso Alven & Blessing A. Aderibigbe. 2023. Viral Infections and Antiviral Therapies. Viral Infections and Antiviral Therapies 407 492 .
Bumi Herman, Andrea Bruni, Ekachaeryanti Zain, Azhar Dzulhadj & Aye Chan Oo. (2022) Post-COVID depression and its multiple factors, does Favipiravir have a protective effect? A longitudinal study of indonesia COVID-19 patients. PLOS ONE 17:12, pages e0279184.
Crossref
Maisha Farzana, Sagarika Shahriar, Faria Rahman Jeba, Tahani Tabassum, Yusha Araf, Md. Asad Ullah, Jarin Tasnim, Agnila Chakraborty, Taslima Anjum Naima, Kay Kay Shain Marma, Tanjim Ishraq Rahaman & Mohammad Jakir Hosen. (2022) Functional food: complementary to fight against COVID-19. Beni-Suef University Journal of Basic and Applied Sciences 11:1.
Crossref
Pooja Yadav & Papia Chowdhury. (2022) Effectivity of repurposed drugs against SARS-CoV-2 infections, A hope for COVID 19: inhibitor modelling studies by docking and molecular dynamics. Heliyon 8:12, pages e12327.
Crossref
Fatma Ozlem Zurnaci & Mustafa Guzel. (2022) The Effects of Increased Glucose Level and Glycolysis on SARS CoV-2 Infection. Mini-Reviews in Medicinal Chemistry 22:18, pages 2344-2349.
Crossref
Mehmet Sami Islamoglu, Mehmet Dokur, Betul Borku Uysal & Burak Onal. (2022) Angioedema after favipiravir treatment: Two cases. Journal of Cosmetic Dermatology 21:9, pages 3704-3706.
Crossref
Abdullah Ibrahim Aedh. (2022) Junctional bradycardia in a patient with COVID-19: A case report. World Journal of Clinical Cases 10:24, pages 8755-8760.
Crossref
Suzana Corritori, Nikolay Savchuk & C. David Pauza. (2022) Risk/Benefit Profiles of Currently Approved Oral Antivirals for Treatment of COVID-19: Similarities and Differences. COVID 2:8, pages 1057-1076.
Crossref
Jency Roshni, R. Vaishali, KS Ganesh, N. Dharani, Khalid J. Alzahrani, Hamsa Jameel Banjer, Ali H. Alghamdi, Abdulrahman Theyab, Shiek SSJ Ahmed & Shankargouda Patil. (2022) Multi-target potential of Indian phytochemicals against SARS-CoV-2: A docking, molecular dynamics and MM-GBSA approach extended to Omicron B.1.1.529.. Journal of Infection and Public Health 15:6, pages 662-669.
Crossref
Majid Mohammed Mahmood. (2022) COVID-19 and Blood Clots: Is it only The Virus to be Blamed? What are new Updates? A Systematic Review. Journal of Cardiology and Cardiovascular Research.
Crossref
Sedigheh Rafiei Tabatabaei, Omid Moradi, Abdollah Karimi, Shahnaz Armin, Alireza Fahimzad, Roxana Mansour Ghanaie, Mahnaz Jamee, Azam Mousavizadeh, Hossein Amini & Bahador Mirrahimi. (2022) A Single-Centered Cohort Study on Favipiravir Safety and Efficacy in Pediatric Patients with COVID-19. Iranian Journal of Pharmaceutical Research 21:1.
Crossref
Mei Nee Chiu, Maitry Bhardwaj & Sangeeta Pilkhwal Sah. (2022) Safety profile of COVID-19 drugs in a real clinical setting. European Journal of Clinical Pharmacology 78:5, pages 733-753.
Crossref
Olga Yu. Kuznetsova. (2022) Etiotropic therapy of the new coronavirus infection: expectations and realities at the beginning of 2022. Part 1. Russian Family Doctor 26:1, pages 7-14.
Crossref
Abdullahi Rabiu Abubakar, Rahnuma Ahmad, Adekunle Babajide Rowaiye, Sayeeda Rahman, Katia Iskandar, Siddhartha Dutta, Angus Nnamdi Oli, Sameer Dhingra, Maryam Abba Tor, Ayukafangha Etando, Santosh Kumar, Mohammed Irfan, Marshall Gowere, Kona Chowdhury, Farhana Akter, Dilshad Jahan, Natalie Schellack & Mainul Haque. (2022) Targeting Specific Checkpoints in the Management of SARS-CoV-2 Induced Cytokine Storm. Life 12:4, pages 478.
Crossref
Paul Andrei Negru, Andrei-Flavius Radu, Cosmin Mihai Vesa, Tapan Behl, Mohamed M. Abdel-Daim, Aurelia Cristina Nechifor, Laura Endres, Manuela Stoicescu, Bianca Pasca, Delia Mirela Tit & Simona Gabriela Bungau. (2022) Therapeutic dilemmas in addressing SARS-CoV-2 infection: Favipiravir versus Remdesivir. Biomedicine & Pharmacotherapy 147, pages 112700.
Crossref
Burcu Kaya, Dilek Barutcu Atas, Elif Tukenmez Tigen, Ebru Asicioglu, Hakki Arikan, Serhan Tuglular & Arzu Velioglu. (2022) Favipiravir Use in Kidney Transplant Recipients with COVID-19: A Single-Center Experience. Experimental and Clinical Transplantation 20:2, pages 143-149.
Crossref
Siddhartha Dutta, Rimplejeet Kaur, Jaykaran Charan, Pankaj Bhardwaj, Sneha R Ambwani, Shoban Babu, Jagdish P Goyal & Mainul Haque. (2022) Analysis of Neurological Adverse Events Reported in VigiBase From COVID-19 Vaccines. Cureus.
Crossref
Siddhartha Dutta, RimpleJ Kaur, Pankaj Bhardwaj, Sneha Ambwani, Brian Godman, PallaviA Jha, Sanchi Sukhija, SumanS Venkatesh, Halyna Lugova, Salequl Islam, Jaykaran Charan & Mainul Haque. (2022) Demand of COVID-19 medicines without prescription among community pharmacies in Jodhpur, India: Findings and implications. Journal of Family Medicine and Primary Care 11:2, pages 503.
Crossref
Pradeep Balasubramanian, Chhakchhuak Laldinthari & Robert Lalnunpuia. (2022) Mucocutaneous adverse effects of remdesivir and favipiravir in patients with Covid-19 infection: A systematic review. Indian Journal of Dermatopathology and Diagnostic Dermatology 9:2, pages 47.
Crossref
Rujittika Mungmunpuntipantip & Viroj Wiwanitkit. (2022) Correspondence on ‘Coronavirus disease 2019 in patients with cardiovascular disease’. Journal of Cardiovascular Medicine 23:1, pages e42.
Crossref
Michael D. Waters, Stafford Warren, Claude Hughes, Philip Lewis & Fengyu Zhang. (2022) Human genetic risk of treatment with antiviral nucleoside analog drugs that induce lethal mutagenesis: the special case of molnupiravir. Environmental and Molecular Mutagenesis 63:1, pages 37-63.
Crossref
Selim Gök, Ömer Faruk Bahçecioğlu, Mefküre Durmuş, Zeynep Ülkü Gün, Yasemin Ersoy, Zeynep Ayfer Aytemur & Özkan Ulutaş. (2021) The safety profile of favipiravir in COVID‐19 patients with severe renal impairment. International Journal of Clinical Practice 75:12.
Crossref
Zinnet Şevval Aksoyalp & Dilara Nemutlu-Samur. (2021) Sex-related susceptibility in coronavirus disease 2019 (COVID-19): Proposed mechanisms. European Journal of Pharmacology 912, pages 174548.
Crossref
Vivek P. Chavda, Normi Gajjar, Nirav Shah & Divyang J. Dave. (2021) Darunavir ethanolate: Repurposing an anti-HIV drug in COVID-19 treatment. European Journal of Medicinal Chemistry Reports 3, pages 100013.
Crossref
Ahmed S. Ali, Ibrahim M. Ibrahim, Abdulhadi S. Burzangi, Ragia H. Ghoneim, Hanin S. Aljohani, Hamoud A. Alsamhan & Jehan Barakat. (2021) Scoping insight on antiviral drugs against COVID-19. Arabian Journal of Chemistry 14:10, pages 103385.
Crossref
Ahmed Serkan Emekli, Asuman Parlak, Nejla Yılmaz Göcen & Murat Kürtüncü. (2021) Anti-GAD associated post-infectious cerebellitis after COVID-19 infection. Neurological Sciences 42:10, pages 3995-4002.
Crossref
Md. Jamal Hossain, Tabassum Jannat, Shejuti Rahman Brishty, Urmi Roy, Saikat Mitra, Md. Oliullah Rafi, Md. Rabiul Islam, Mst. Luthfun Nesa, Md. Ariful Islam & Talha Bin Emran. (2021) Clinical Efficacy and Safety of Antiviral Drugs in the Extended Use against COVID-19: What We Know So Far. Biologics 1:2, pages 252-284.
Crossref
Abhigyan Choudhury, Gargi Mukherjee & Suprabhat Mukherjee. (2021) Chemotherapy vs. Immunotherapy in combating nCOVID19: An update. Human Immunology 82:9, pages 649-658.
Crossref
Mohammad Hailat, Israa Al-Ani, Mohammed Hamad, Zainab Zakareia & Wael Abu Dayyih. (2021) Development and Validation of a Method for Quantification of Favipiravir as COVID-19 Management in Spiked Human Plasma. Molecules 26:13, pages 3789.
Crossref
Duygu Eryavuz Onmaz, Sedat Abusoglu, Mustafa Onmaz, Fatma Humeyra Yerlikaya & Ali Unlu. (2021) Development and validation of a sensitive, fast and simple LC-MS / MS method for the quantitation of favipiravir in human serum. Journal of Chromatography B 1176, pages 122768.
Crossref
Dang The Hung, Suhaib Ghula, Jeza Abdul Aziz, Abdelrahman M. Makram, Gehad Mohamed Tawfik, Ali Ahmed-Fouad Abozaid, Rohan Andrew Pancharatnam, Amr Mohamed Ibrahim, Muhammad Besher Shabouk, Morgan Turnage, Saloni Nakhare, Zahra Karmally, Basel Kouz, Tran Nhat Le, Suleiman Alhijazeen, Nguyen Quoc Phuong, Alaa Mohamed Ads, Ali Hussein Abdelaal, Nguyen Hai Nam, Tatsuo Iiyama, Kyoshi Kita, Kenji Hirayama & Nguyen Tien Huy. (2021) The Efficacy and Adverse Effects of Favipiravir on COVID-19 Patients: A Systematic Review and Meta-Analysis of Published Clinical Trials and Observational Studies. SSRN Electronic Journal.
Crossref